posted on 2016-03-23, 00:00authored byShao-Lin Zhang, Xiaohui Hu, Wen Zhang, Kin Yip Tam
Pyruvate
dehydrogenase kinases (PDKs) have recently emerged as
an attractive target for cancer therapy. Herein, we prepared a series
of compounds derived from dichloroacetate (DCA) which inhibited cancer
cells proliferation. For the first time, we have successfully developed
DCA derived inhibitors that preferentially bind to the adenosine triphosphate
(ATP) pocket of PDK isoform 1 (PDK1).